[1] 国家统计局,国务院第七次全国人口普查领导小组办公室. 第七次全国人口普查公报[1] [R/OL]. [2021-10-13] . http://www.gov.cn/guoqing/2021-05/13/content_5606149.htm.
[2] 中国疾病控制中心慢性非传染性疾病预防控制中心,中华医学会骨质疏松和骨矿盐疾病分会. 中国骨质疏松症流行病学调查报告(2018)[M].北京:人民卫生出版社,2021.
[3] 朱洁云,高敏,宋秋韵,等. 中国老年人骨质疏松症患病率的Meta分析[J]. 中国全科医学,2022,25(3):346-353.
[4] 章振林,金小岚,夏维波. 原发性骨质疏松症诊疗指南(2017版)要点解读[J]. 中华骨质疏松和骨矿盐疾病杂志,2017,10(5):411-412.
[5] 张英泽. 老年骨质疏松性骨折的防治焦点[J]. 中华老年骨科与康复电子杂志, 2021, 7(1):1.
[6] CAMPISI J, KAPAHI P, LITHGOW G J, et al. From discoveries in ageing research to therapeutics for healthy ageing[J]. Nature, 2019, 571(7764):183-192.
[7] WATANABE S, KAWAMOTO S, OHTANI N, et al. Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases[J]. Cancer Sci, 2017, 108(4):563-569.
[8] MELGAR K, WALKER M M, JONES L M, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways[J]. Sci Transl Med, 2019, 11(508):eaaw8828.
[9] FRANCESCHI C. Inflammaging as a major characteristic of old people: can it be prevented or cured?[J]. Nutr Rev, 2007, 65(12 Pt 2):S173-S176.
[10] WU Q, ZHOU X, HUANG D, et al. IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro[J]. Cell Physiol Biochem, 2017, 41(4):1360-1369.
[11] WU L, GUO Q, YANG J, et al. Tumor necrosis factor alpha promotes osteoclast formation via PI3K/Akt pathway-mediated blimp1 expression upregulation[J]. J Cell Biochem, 2017, 118(6):1308-1315.
[12] MUMM J B, EMMERICH J, ZHANG X, et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance[J]. Cancer Cell, 2011, 20(6):781-796.
[13] AZIZIEH F Y, SHEHAB D, AL J K, et al. Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD[J]. J Inflamm Res, 2019, 12:99-108.
[14] FARR J N, FRASER D G, WANG H, et al. Identification of senescent cells in the bone microenvironment[J]. J Bone Miner Res, 2016, 31(11):1920-1929.
[15] 王凯, 宋敏, 文皓楠, 等. 从OPG/RANK/RANKL信号转导系统探讨老年性骨质疏松的发病机制[J]. 中国骨质疏松杂志, 2020, 26(6):910-914.
[16] CHMIELNICKA M, WOZNIACKA A, TORZECKA J D. The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus[J]. Postepy Dermatol Alergol, 2014, 31(5):281-288.
[17] TU P, DUAN P, ZHANG R S, et al. Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women[J]. Osteoporos Int, 2015, 26(1):179-185.
[18] RAISZ L G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects[J]. J Clin Invest, 2005, 115(12):3318-3325.
[19] CORALLINI F, CELEGHINI C, RIMONDI E, et al. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells[J]. J Cell Physiol, 2011, 226(9):2279-2286.
[20] KOTAKE S, UDAGAWA N, TAKAHASHI N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis[J]. J Clin Invest, 1999, 103(9):1345-1352.
[21] 薛磊, 苏东月, 葛振英. Graves病患者外周血Treg/Th17及相关细胞因子与骨密度的相关性[J]. 中国实用医刊, 2021, 48(7):25-28.
[22] 王建忠, 王坤正, 时志斌, 等. 长期应用糖皮质激素对大鼠股骨头骨组织OPG/RANKL mRNA表达的影响[J]. 西安交通大学学报(医学版), 2008, 29(6):629-632.
[23] 张毅, 匡红英, 牛二龙, 等. 阿司匹林通过抑制大鼠破骨细胞RANK表达抑制骨质吸收[J]. 中国骨质疏松杂志, 2013, 19(12):1219-1223.
[24] TROUVIN A P, GOEB V. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss[J]. Clin Interv Aging, 2010, 5:345-354.
[25] LIU X Y, XU L, WANG Y, et al. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/NF-kappaB pathway[J]. Int Immunopharmacol, 2017, 44:105-114.
[26] KARST M, GORNY G, GALVIN R J, et al. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation[J]. J Cell Physiol, 2004, 200(1):99-106.
[27] SARIBAL D, HOCAOGLU-EMRE F S, ERDOGAN S, et al. Inflammatory cytokines IL-6 and TNF-alpha in patients with hip fracture[J]. Osteoporos Int, 2019, 30(5):1025-1031.
[28] 罗丽梅, 李杰, 杨帆, 等. 骨质疏松发病机制及治疗药物研究进展[J]. 中国骨质疏松杂志, 2020, 26(4):610-614, 624.
[29] 赵赫, 王文涛, 郭昕宇, 等. 狄诺塞麦(Denosumab)在骨质疏松症治疗中的研究进展[J]. 中国骨质疏松杂志, 2019, 25(3):398-403.
[30] 杨如会, 沈祥春, 任光友, 等. 骨质疏松症治疗药物研究进展[J]. 中国骨质疏松杂志, 2007, 13(6):436-439, 405.
[31] XU M, TCHKONIA T, DING H, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age[J]. Proc Natl Acad Sci U S A, 2015, 112(46):E6301-E6310.
[32] SHANG D, SUN D, SHI C, et al. Activation of epidermal growth factor receptor signaling mediates cellular senescence induced by certain pro-inflammatory cytokines[J]. Aging Cell, 2020, 19(5):e13145.
[33] KANDASAMY M, ANUSUYADEVI M, AIGNER K M, et al. TGF-beta signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia?[J]. Aging Dis, 2020, 11(4):828-850. |
